See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.
Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Recognized by America's Top Doctors, 2012 - 2018
Recognized by Best Doctors in America 2011, 2012, 2015 - 2018
Recognized in Philadelphia magazine's annual Top Docs issues, 2018 - 2020
Penn Presbyterian Medical Center
51 N. 39th Street
Philadelphia, PA 19104
A facility of Penn Presbyterian Medical Center
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Dr. Joan O’Brien has extensive expertise in the study of the genetics of ocular diseases including retinoblastoma, melanoma and glaucoma. Dr. O’Brien’s laboratory has identified numerous unique pathogenic variants in the retinoblastoma gene (RB1). This testing has allowed retinoblastoma therapy to be directed according to underlying genetic risk, and is offered nationwide at no charge to patients through NEI’s eyeGENE™ initiative. Dr. O’Brien directs a research laboratory with next generation sequencing and high-throughput, automated Sanger sequencing capabilities, which focuses on translational genetics research with an emphasis on molecular sub-classification and endophenotyping of ocular disease. Currently, Dr. O’Brien is the primary investigator on an $11.25 million 5-year Primary Open Angle African American Glaucoma Genetics (POAAGG) study. Clinical TrialsDr. O’Brien has 15 years of National Cancer Institute funded leadership roles in clinical trials and phenotype validation for all retinoblastoma studies administered through the Children’s Oncology Group (COG). Over the past five years, in collaboration with colleagues at UCSF, the group has discovered and characterized two novel oncogenes (GNAQ, Nature 2009 and GNA11, NEJM 2010) which regulate the MAP kinase pathway. This has allowed Dr. O’Brien’s uveal melanoma patients to have personalized and targeted therapy with MEK inhibitors, providing prolongation of life for these patients with widely metastatic melanoma.Key Wordsretinoblastoma, melanoma, genetics research, glaucoma
O'Brien JM: Association between Primary Open-Angle Glaucoma and Cognitive Impairment as Measured by the Montreal Cognitive Assessment. Journal of Ophthalmology : 2020.
Chavali VRM, Mills J, Sergei N, Haider N, Rathi S, Vrathasha V, Alapati T, He J, Thuong T, McDougald D, O'Brien J: "Dual SMAD inhibition and Wnt inhibition enable efficient and reproducible differentiations of induced pluripotent stem cells into retinal ganglion cells. Scientific Reports : 2020.
O'Brien JM, Childrens Oncology Group: A single arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma, a Children’s Oncology Group Study. Pediatric Blood & Cancer : 2020.
Kikut A, Vaughn M, Salowe R, Sanyal M, Merriam S, Lee R, Becker E, Lomax-Reese S, Lewis M, Ryan R, Ross A, Cui QN, Addis V, Sankar PS, Miller-Ellis E, Cannuscio C, O’Brien JM: Evaluation of a Multimedia Marketing Campaign to Engage African American Patients in Glaucoma Screening. Preventative Medicine Reports 17 : 2020.
Jubran R, Villablanca J, Krailo M, Piao J, Huang L, O'Brien J, Gombos D, Shields C, Meadows, Chinta MX: A single arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma, a Children’s Oncology Group Study (ARET 0231). Pediatric Blood and Cancer : 2020.
Verkuil L, Danford I, Pistilli M, Collins DW, Gudiseva VF, Trachtman B, He J, Haider N, Ramakrishnan M, Chavali VRM, O’Brien JM: A SNP (rs4657473), located in an AluJb repeat downstream of TMCO1, is protective for POAG in African Americans. British Journal of Ophthalmology 103 : 1530-36,2019.
Chévez-Barrios P, Eagle Jr RC, Krailo M, Piao J, Albert DM, Gao Y, Vemuganti G, Ali MJ, Khetan V, Honaver SG, O’Brien JM, Leahey, AM, Matthay K, Meadows A, Chintagumpala M: Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children’s Oncology Group Study. Journal of Clinical Oncology 18 : 2019.
Khachatryan N, Pistilli M, Maguire M, Salowe R, Fertig R, Moore T, Gudiseva HV, Chavali VRM, Collins DW, Daniel E, Murphy W, Henderer JD, Lehman A, Cui Q, Addis V, Sankar P, Miller-Ellis EG, O’Brien JM: Primary Open-Angle African American Glaucoma Genetics (POAAGG) Study: Gender and Risk of POAG in African Americans. PLOS One 14 (8): e0218804,2019.
Addis V, Oyeniran E, Daniel E, Salowe R, Zorger R, Lee R, Pistilli M, Maguire M, Cui Q, Miller-Ellis E, O’Brien JM, Sankar PS: Non-Physician Grader Reliability in Measuring Morphological Features of the Optic Nerve Head in Stereo Digital Images. Nature Eye (London) 33 (5): 838-844,2019.
Gudiseva H, Pistilli M, Salowe R, Singh L, Collins D, Cole B, He J, Sayaka M, Khachataryan N, Henderer J, Addis V, Cui Q, Sankar P, Miller-Ellis E, Chavali V, Ying G, Wallace D, O'Brien J: The Association of mitochondrial DNA haplogroups with POAG in African Americans Experimental Eye Research 181 : 85-89,2019.
University of PennsylvaniaScheie Eye InstituteDepartment of Ophthalmology51 N. 39th Street
Patient appointments: 800-789-7366